Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients.
anti-HBs
entecavir
hepatitis B virus
lymphoma
reactivation
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
25
09
2023
received:
14
07
2023
accepted:
25
09
2023
medline:
15
11
2023
pubmed:
7
10
2023
entrez:
6
10
2023
Statut:
ppublish
Résumé
This study aimed to investigate a stratified approach based on hepatitis B virus (HBV) surface antibody (anti-HBs) for managing HBV reactivation (HBVr) in lymphoma patients with serological protection against HBV. A retrospective analysis was conducted on 209 lymphoma patients with a baseline anti-HBs titre of ≥10 iu/L, who were either positive or negative for HBV core antibody (anti-HBc). The results revealed that 15.7% of patients lost serological protection following 6-month anti-lymphoma therapy. With a median follow-up of 28.1 months, the cumulative rates of HBVr at 6 months, 2 years and 4 years were 2.9%, 4.7% and 6.3% respectively. Without intervention, the overall rate of reactivation was 2.0% for patients with isolated anti-HBs and 10.5% for those with positive anti-HBs and anti-HBc. To identify patients at high risk of losing seroprotection and susceptible to HBVr, a predictive model was developed. The high-risk group had significantly higher rates of serological protection loss (27.8% vs. 2.2%) and cumulative incidence of HBVr (22.0% vs. 0%) compared to the low-risk group. Overall, this study highlights the risk of HBVr in lymphoma patients with positive anti-HBs, with or without positive anti-HBc, and recommends periodic monitoring for low-risk patients and early intervention for high-risk patients.
Substances chimiques
Rituximab
4F4X42SYQ6
Hepatitis B Surface Antigens
0
Hepatitis B Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
571-580Informations de copyright
© 2023 British Society for Haematology and John Wiley & Sons Ltd.
Références
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403. https://doi.org/10.1016/S2468-1253(18)30056-6
Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299-307. https://doi.org/10.1002/1096-9071(200011)62:3<299::aid-jmv1>3.0.co;2-0
Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27(4):605-611. https://doi.org/10.1200/JCO.2008.18.0182
Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 2013;33(2):167-177. https://doi.org/10.1055/s-0033-1345722
Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215-219; quiz e16-7. https://doi.org/10.1053/j.gastro.2014.10.039
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Dis (Hoboken). 2018;12(1):33-34. https://doi.org/10.1002/cld.728
Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-3715. https://doi.org/10.1200/JCO.20.01757
Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15(5):1031-1048. https://doi.org/10.1007/s12072-021-10239-x
Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652-657. https://doi.org/10.1016/j.jhep.2008.07.014
Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71(2):397-408. https://doi.org/10.1016/j.jhep.2019.03.034
Paul S, Dickstein A, Saxena A, Terrin N, Viveiros K, Balk EM, et al. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology. 2017;66(2):379-388. https://doi.org/10.1002/hep.29082
Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32(33):3736-3743. https://doi.org/10.1200/JCO.2014.56.7081
Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61(5):719-729. https://doi.org/10.1093/cid/civ344
Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315(4):209-214. https://doi.org/10.1056/NEJM198607243150401
Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-244.e3. https://doi.org/10.1053/j.gastro.2014.10.038
Mozessohn L, Chan KK, Feld JJ, Hicks LK. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22(10):842-849. https://doi.org/10.1111/jvh.12402
Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol. 2013;57(3):209-214. https://doi.org/10.1016/j.jcv.2013.03.010
Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59-68. https://doi.org/10.1053/j.gastro.2006.04.015
Awerkiew S, Däumer M, Reiser M, Wend UC, Pfister H, Kaiser R, et al. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol. 2007;38(1):83-86. https://doi.org/10.1016/j.jcv.2006.10.006
Ferreira R, Carvalheiro J, Torres J, Fernandes A, Giestas S, Mendes S, et al. Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: a case report and literature review. Saudi. J Gastroenterol. 2012;18(4):277-281. https://doi.org/10.4103/1319-3767.98436
Jun CH, Kim BS, Oak CY, Lee DH, Cho E, Cho SB, et al. HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea. Hepatol Int. 2017;11(1):87-95. https://doi.org/10.1007/s12072-016-9747-0
Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010;51(5):1531-1537. https://doi.org/10.1002/hep.23464
Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297-1309. https://doi.org/10.1053/j.gastro.2017.02.009
Shui LP, Zhu Y, Duan XQ, Chen YT, Yang L, Tang XQ, et al. HBsAg (−)/HBsAb (−)/HBeAg (−)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy. J Med Virol. 2023;95(2):e28549. https://doi.org/10.1002/jmv.28549
Pei SN, Liu YF, Kuo CY, Wang MC, Ma MC, Liao CK, et al. Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab. Leuk Lymphoma. 2021;62(12):2899-2906. https://doi.org/10.1080/10428194.2021.1948034
Takahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K, et al. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis. 2014;16(5):797-801. https://doi.org/10.1111/tid.12283
Onozawa M, Hashino S, Darmanin S, Okada K, Morita R, Takahata M, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant. 2008;14(11):1226-1230. https://doi.org/10.1016/j.bbmt.2008.08.007